Insights
Research pipeline intelligence across every condition we track: where late-stage research is concentrated, where Australians can access trials, and where the gaps are. Sourced from public government registries and updated nightly. This is not medical advice.
Your followed conditions
Create a free account and follow the conditions you care about. This panel will then show their live numbers, recruiting trials, Australian sites, and PBS medicines, every time you visit.
Breast Cancer has the most currently recruiting Phase 3 trials of any condition we track: 98 late-stage trials worldwide
Prostate Cancer has 47 recruiting trials with Australian sites, the most local access of any condition on the platform
The Australian access gap
For the conditions with the most currently recruiting late-stage (Phase 3) trials worldwide, that recruiting count is shown alongside how many of those trials have Australian sites. The gap between them is where Australians are locked out.
Phase 3 counts are currently recruiting Phase 3 trials from the latest nightly condition snapshot (sourced from ClinicalTrials.gov), the same source as the Australian site counts beside them. Australian site counts come from ClinicalTrials.gov only: trials registered solely with ANZCTR are not counted, so the Australian bars understate local access and the gap shown is a maximum, not a measurement. Site flags may not capture every location. Verify current status on individual condition pages.
Government health research funding: Australia vs peers
How much a government budgets for health research, compared across a few countries. This is the OECD's measure of government budget allocations for R&D directed at health (GBARD, socio-economic objective 07). It is a funding commitment, not health spending, not the number of trials running, and not whether Australians can access them.
Not adjusted for population. These are whole-country totals, not per-person figures, and they are not adjusted for how many people each country has. A country with a larger population will tend to show a larger total whatever its priorities, so this comparison understates Australia against more populous countries such as the United Kingdom and overstates it against smaller ones such as New Zealand. Read the bars as the size of each budget, not as how strongly a country favours health research, and do not read the order as a ranking of commitment.
Figures in constant 2020 prices (USD PPP, millions). Each country's most recent available year is shown, and those years do not all line up.
Canada's figure is defined differently to other countries, per OECD's data-quality notes.
Australia's figure is defined differently to other countries, estimated, and provisional, per OECD's data-quality notes.
Australia's figure here is 1,092 in constant 2020 prices. On a current-prices basis the same budget is 1,407, about 29% higher, so the price basis is stated rather than left to chance. Australia's own figure is also defined differently to other countries, estimated, and provisional in the OECD's records, which is why it is best read as an order-of-magnitude comparison, not an exact ranking.
Source: OECD, Government Budget Allocations for R&D (GBARD), socio-economic objective 07 (Health), in US dollars at purchasing power parity. Licence: Creative Commons Attribution 4.0 (CC BY 4.0). Caveat: OECD's terms-of-use page was unreachable from our systems (HTTP 403) when checked on 17 and 18 July 2026, so this licence rests on OECD's published licensing statements rather than a direct read of that page. These are government budget commitments, not expenditure, health outcomes, or trial activity.
Biggest movers this week
Coming soon. We have enough snapshot history for a week-on-week comparison, but our trials catalogue is still catching up on registry records, so this week's change would mostly reflect how fast we indexed each condition rather than real movement in its research. This section will appear once our nightly sync settles.
More insights in development
These are not built yet. We'll notify subscribers when each one launches.
Most active research pipelines
Conditions with the most currently recruiting Phase 3 (late-stage) trials worldwide. Source: the nightly condition snapshot (condition_monthly_snapshots.phase3_count), recomputed from the full trials table of ClinicalTrials.gov data. This is a narrower measure than the cumulative pipeline dataset, which counts registered trials of any status.
| Condition | Phase 3 trials | Recruiting | AU sites |
|---|---|---|---|
| Breast Cancer | 98 | 880 | 22 |
| Lung Cancer | 96 | 886 | 31 |
| Head and Neck Cancer | 77 | 516 | 7 |
| Prostate Cancer | 69 | 781 | 47 |
| Stroke | 65 | 913 | 16 |
| Colorectal Cancer | 61 | 614 | 14 |
| Lymphoma | 61 | 758 | 39 |
| Stomach Cancer | 59 | 570 | 27 |
| Leukaemia | 56 | 612 | 40 |
| Myeloma | 56 | 493 | 44 |
Compare conditions
Put two or three conditions side by side: recruiting trials worldwide, how many of them Australians can actually reach, the phase split, and PBS-subsidised medicines.
For example: Breast Cancer vs Lung Cancer.
Australian access spotlight
Conditions with the most recruiting trials running at Australian sites, where local trial access is strongest.
| Condition | Recruiting trials with AU sites | Recruiting (global) |
|---|---|---|
| Prostate Cancer | 47 | 781 |
| Myeloma | 44 | 493 |
| Leukaemia | 40 | 612 |
| Lymphoma | 39 | 758 |
| Melanoma | 34 | 325 |
Australian site counts come from ClinicalTrials.gov only. Trials registered solely with ANZCTR are not counted, so these figures understate local access.
Where the trials are, state by state
Recruiting trials with at least one site in each state or territory. This is trial access, not trial count: it asks where in Australia you could actually join a study.
These numbers overlap and do not add up to 910. A trial running in both Melbourne and Sydney is available to patients in both states, so it is counted in both. Adding the column together would count the same trial several times.
Of the 910 recruiting trials we track with an Australian site, we can place 848 (93%) in a specific state. The remaining 62 list an Australian location without a state or postcode we can resolve, so they are not in the chart above. We would rather leave them out than guess a state you might travel interstate on. Check the trial's own record for its exact locations.
These are raw counts, so the larger states lead them by construction. For the same figures set against each state's population, see trial access equity by state.
Research gap: high global activity, limited Australian access
Conditions with meaningful worldwide recruiting Phase 3 research activity but no recruiting trials at Australian sites in the latest snapshot. High research activity worldwide, limited Australian trial access.
These conditions have no recruiting Australian trial in the registries we sync. We do not yet include the Australian New Zealand Clinical Trials Registry (ANZCTR), and some Australian trials register only there, so this list likely overstates the gap. Search ANZCTR directly before concluding no Australian trial exists.
FDA-to-PBS access lag
Coming soon, accumulating data.
Once enough drugs have moved from FDA approval through to PBS listing, this section will show the average time Australians wait for subsidised access after a drug is first approved overseas, segmented by drug class and condition category.
This metric requires paired FDA approval and PBS listing dates, which accumulate over time as drugs progress through the access chain. It is not yet statistically meaningful and is withheld until it is.
Most active research sponsors
Organisations running the most trials that are currently recruiting, counted across every tracked condition. Source: ClinicalTrials.gov sponsor data, aggregated nightly.
Counted over the 149 sponsors in our sponsor directory, with each organisation's alternative registry spellings merged so it is counted once rather than split across them. A trial is counted once per sponsor however many conditions it is tagged to. This is a different measure from the sponsor table on our statistics page, which ranks by total trials on record rather than by trials recruiting now.
M.D. Anderson Cancer Center leads on trials recruiting now (248), against 1594 trials on record in total — a reminder that the largest research portfolio and the most open recruitment are not the same thing.
Research equity
Which conditions have the fewest clinical trials relative to the number of Australians affected? Research equity reveals where patients are underserved.
Full rankings arrive once Australian prevalence data is loaded. See the methodology for how this is computed.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Figures are computed from public government registries (ClinicalTrials.gov, NIH Reporter, openFDA) and Voxsanity's nightly condition snapshots. Latest snapshot: 28 July 2026. See our methodology for definitions. This page does not constitute medical advice.